Edison Investment Research today published a report on Zeltia entitled "Charting A Course Into Clearer Waters". In summary, the report says:
*.- Zeltia has made significant progress in weathering the storms of recent years. *.- FY13 results demonstrate improved profitability and cash flows, which have further reduced the debt burden.
*.- Ex-US ex-Japan Yondelis sales have resumed their growth trajectory (net revenues up 10% to €73m) following the resolution of Doxil supply issues in May. Looking forward, clinical data in H214 for Zeltia's two key products could be transformative.
*.- Janssen's 2015 FDA filing of Yondelis rests on positive Phase III sarcoma results, while Taiho could file in Japan by year-end on the back of its pivotal Phase II study.
*.- Full data from the Phase II PM01183 study in ovarian cancer could form the basis of a lucrative licensing deal.
...